Kendall Capital Management Grows Stake in Regeneron Pharmaceuticals Inc (REGN)

Share on StockTwits

Kendall Capital Management raised its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 54.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,329 shares of the biopharmaceutical company’s stock after purchasing an additional 471 shares during the quarter. Kendall Capital Management’s holdings in Regeneron Pharmaceuticals were worth $546,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in REGN. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $292,457,000. FMR LLC raised its holdings in shares of Regeneron Pharmaceuticals by 6.6% in the 4th quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after purchasing an additional 330,875 shares during the period. Morgan Stanley raised its holdings in shares of Regeneron Pharmaceuticals by 70.6% in the 3rd quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after purchasing an additional 192,236 shares during the period. Parnassus Investments CA purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $65,699,000. Finally, American Century Companies Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 16.6% in the 4th quarter. American Century Companies Inc. now owns 1,003,471 shares of the biopharmaceutical company’s stock worth $374,796,000 after purchasing an additional 142,779 shares during the period. Institutional investors own 67.63% of the company’s stock.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the sale, the director now owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 141,968 shares of company stock valued at $57,360,056. Insiders own 11.84% of the company’s stock.

REGN stock opened at $309.63 on Tuesday. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals Inc has a 1 year low of $291.10 and a 1 year high of $442.00. The stock has a market capitalization of $33.06 billion, a PE ratio of 15.64, a P/E/G ratio of 1.44 and a beta of 1.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The company had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.76 billion. During the same quarter last year, the business posted $4.67 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 13.3% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals Inc will post 18.37 earnings per share for the current year.

A number of equities analysts have recently commented on REGN shares. Cantor Fitzgerald restated a “hold” rating and issued a $441.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. BidaskClub downgraded Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, April 25th. Oppenheimer raised their price objective on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the stock an “outperform” rating in a report on Thursday, February 7th. Jefferies Financial Group cut their price objective on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in a report on Wednesday, April 17th. Finally, Canaccord Genuity restated a “hold” rating and issued a $353.00 price objective (down from $408.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, May 8th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $400.82.

WARNING: This piece of content was reported by Highlight Press and is the property of of Highlight Press. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://highlightpress.com/2019/05/21/kendall-capital-management-grows-stake-in-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: What is a blue-chip stock?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.